← FDA DRUG APPROVALS

FDA NDA · NDA018749

LITHOSTAT

acetohydroxamic acid

Sponsor: MISSION PHARMA

APPLICATION
NDA018749
TYPE
NDA
ORIGINAL APPROVAL
1983-05-31
LATEST ACTION
2015-01-26
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LITHOSTAT · ReferencePrescription
ACETOHYDROXAMIC ACID 250MG · TABLET · ORAL

Approval history

2015-01-26Manufacturing (CMC) · Supplement 9 · priorityAP
2000-05-19Manufacturing (CMC) · Supplement 7 · priorityAP
1988-08-03Labeling · Supplement 6AP
1986-08-06Manufacturing (CMC) · Supplement 4 · priorityAP
1984-11-05Manufacturing (CMC) · Supplement 2 · priorityAP
1984-01-11Manufacturing (CMC) · Supplement 3 · priorityAP
1983-11-18Labeling · Supplement 1AP
1983-05-31Type 1 - New Molecular Entity · Original · priorityAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →